Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours

Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours

A drug used at the maximum tolerated dose can exert a strong selective pressure on cancer cells leading to resistance. In this study, the authors demonstrate the efficacy of using low dose of multiple drugs for preventing and treating resistance to EGFR tyrosine kinase inhibitors in NSCLC cells.

Bibliographic Details
Main Authors: João M. Fernandes Neto, Ernest Nadal, Evert Bosdriesz, Salo N. Ooft, Lourdes Farre, Chelsea McLean, Sjoerd Klarenbeek, Anouk Jurgens, Hannes Hagen, Liqin Wang, Enriqueta Felip, Alex Martinez-Marti, August Vidal, Emile Voest, Lodewyk F. A. Wessels, Olaf van Tellingen, Alberto Villanueva, René Bernards
Format: Article
Language:English
Published: Nature Portfolio 2020-06-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-020-16952-9

Internet

https://doi.org/10.1038/s41467-020-16952-9

Similar Items